Long-Term Observation of Intravitreal Injection of Ranibizumab Combined with Ozurdex<sup>®</sup> in the Treatment of Retinal Vein Occlusion with Macular Edema

Xuemei Liang; Baiyun Shen•Zuguo Ou; Hongmei An; Li Li

doi:doi:10.11648/j.ijovs.20220704.14

| Peer-Reviewed

Long-Term Observation of Intravitreal Injection of Ranibizumab Combined with Ozurdex^® in the Treatment of Retinal Vein Occlusion with Macular Edema

Xuemei Liang, Baiyun Shen•Zuguo Ou, Hongmei An, Li Li

Published in International Journal of Ophthalmology & Visual Science (Volume 7, Issue 4)

Received: 25 October 2022 Accepted: 11 November 2022 Published: 22 November 2022

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

Background: To evaluate the duration and long-term efficacy of intravitreal injection of ranibizumab (IVR) combined with Ozurdex^® (DEX) in the treatment of retinal vein occlusion with macular edema (RVO-ME). Methods: This retrospective case study included 38 patients with non-ischemic RVO-ME who were initially treated by intravitreal injection of IVR combined with DEX. Patients with recurrence of macular edema continued with IVR+DEX therapy. Data were recorded for all patients at baseline and at 1 week, and 1, 3, 4, 5, 6, 9, and 12 months after treatment. The primary outcome measures were the average reinjection interval and the number of injection needles. Results: The mean interval for reinjection of RVO-ME was 134.2±9.1 days. The average number of injection needles was 4.2±1.1, and 65.8% of patients received 4 injection needles. There was no significant difference in mean reinjection interval and injection needle between central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO) patients. At the end of follow-up, the mean improvement of BCVA in CRVO and BRVO patients was 0.29±0.26 and 0.31±0.33, respectively, and 52.6% (20/38) patients experienced visual acuity improvement of > 3 lines. The average decrease in CFT was 406.0±272.3 μm and 408.2±379.9 μm, respectively, and there was no significant difference between the two types of RVO-ME in BCVA improvement and CFT reduction (p=0.82 and 0.98). Conclusions: Intravitreal injection of ranibizumab combined with Ozurdex^® led to better efficacy, fewer injections, lower medical burden, and more controllable side effects.

Published in	International Journal of Ophthalmology & Visual Science (Volume 7, Issue 4)
DOI	10.11648/j.ijovs.20220704.14
Page(s)	126-130
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2022. Published by Science Publishing Group

Keywords

Retinal Vein Occlusion, Macular Edema, Ranibizumab, Ozurdex^®

References

[1]	Song P, Xu Y, Zha M, et al (2019) Global epidemiology of retinal vein occlusion: a systematic review and meta-analysis of prevalence, incidence, and risk factors. J Glob Health. 9 (1): 010427. https://doi.org/10.7189/jogh.09.010427
[2]	Wang Q, Yang J, Jonas JB, et al (2021) Prevalence of Retinal Vein Occlusions and Estimated Cerebrospinal Fluid Pressure: The Kailuan Eye Study. Eye Brain. 21; 13: 147-156. https://doi.org/ 10.2147/EB.S290107.
[3]	Rehak M, Wiedemann P (2010) Retinal vein thrombosis: pathogenesis and management. J Thromb Haemost. 8 (9): 1886–1894. https://doi.org/10.1111/j.1538-7836.2010.03909.x.
[4]	Koss MJ, Pfister M, Rothweiler F, et al (2012) Comparison of cytokine levels from undiluted vitreous of untreated patients with retinal vein occlusion. Acta Ophthalmol. 90 (2): e98–103. https://doi.org/ 10.1111/j.1755-3768.2011.02292.x.
[5]	Noma H, Funatsu H, Yamasaki M, et al (2005) Pathogenesis of macular edema with branch retinal vein occlusion and intraocular levels of vascular endothelial growth factor and interleukin-6. Am J Ophthalmol. 140: 256-261. https://doi.org/ 10.1016/j.ajo.2005.03.003.
[6]	Chang-Lin JE, Attar M, Acheampong AA, et al (2011) Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant. Invest Ophthalmol Vis Sci. 52: 80–86. https://doi.org/10.1167/iovs.10-5285.
[7]	Gu X, Yu X, Song S, et al (2017) Intravitreal Dexamethasone Implant versus Intravitreal Ranibizumab for the Treatment of Macular Edema Secondary to Retinal Vein Occlusion in a Chinese Population. Ophthalmic Res. 58 (1): 8-14. https://doi.org/ 10.1159/000458534.
[8]	Li X, Wang N, Liang X, Xu G (2018) Safety and efficacy of dexamethasone intravitreal implant for treatment of macular edema secondary to retinal vein occlusion in Chinese patients: randomized, sham-controlled, multicenter study. Graefes Arch Clin Exp Ophthalmol. 256 (1): 59-69. https://doi.org/ 10.1007/s00417-017-3831-6.
[9]	Garay-Aramburu G, Gomez-Moreno A (2018) A 5-Year follow-up study of the treatment of macular edema due to retinal vein occlusion using dexamethasone intravitreal implants. J Ocul Pharmacol Ther. 34: 436–441. https://doi.org/10.1089/jop.2017.0148
[10]	Sivaprasad, S; Amoaku, WM; Hykin, P, RVO Guideline Group (2015) The Royal College of Ophthalmologists Guidelines on retinal vein occlusions: executive summary. Eye (Lond). 29 (12): 1633-8. https://doi.org/10.1038/eye.2015.164.
[11]	Campochiaro PA, Clark WL, Boyer DS, et al (2015) Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study. Ophthalmology. 122 (3): 538–544. https://doi.org/10.1016/j.ophtha.2014.08.031
[12]	Haller JA, Bandello F, Belfort R Jr, et al (2011) Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion: twelve-month study results. Ophthalmology. 118 (12): 2453–2460. https://doi.org/10.1016/j.ophtha.2011.05.014
[13]	Schmidt-Erfurth, U, Garcia-Arumi, J, Gerendas, BS, et al (2019) Guidelines for the Management of Retinal Vein Occlusion by the European Society of Retina Specialists (EURETINA). Ophthalmologica. 242 (3): 123-162. https://doi.org/ 10.1159/000502041
[14]	Singer MA, Jansen ME, Tyler L, et al (2017) Long-term results of combination therapy using anti-VEGF agents and dexamethasone intravitreal implant for retinal vein occlusion: An investigational case series. Clin Ophthalmol. 11: 31–38. https://doi.org/ 10.2147/OPTH.S119373
[15]	Blanc, J; Deschasse, C; Kodjikian, L; et al (2018) Safety and long-term efficacy of repeated dexamethasone intravitreal implants for the treatment of cystoid macular edema secondary to retinal vein occlusion with or without a switch to anti-VEGF agents: a 3-year experience. Graefes Arch Clin Exp Ophthalmol. 256 (8): 1441-1448. https://doi.org/10.1007/s00417-018-4016-7
[16]	Campochiaro PA, Sophie R, Pearlman J, et al (2014) Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN study. Ophthalmology. 121 (1): 209-219. https://doi.org/10.1016/j.ophtha.2013.08.03
[17]	Campochiaro PA, Brown DM, Awh CC, et al (2011) Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology. 118 (10): 2041–2049. https://doi.org/10.1016/j.ophtha.2011.02.038
[18]	Brown DM, Campochiaro PA, Bhisitkul RB, et al (2011) Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology. 118 (8): 1594–1602. https://doi.org/10.1016/j.ophtha.2011.02.022
[19]	Singer MA, Capone A Jr, Dugel PU, et al (2015) Two or more dexamethasone intravitreal implants as monotherapy or in combination therapy for macular edema in retinal vein occlusion: subgroup analysis of a retrospective chart review study. BMC Ophthalmol. 15: 33. https://doi.org/ 10.1186/s12886-015-0018-y.
[20]	Rajesh B, Zarranz-Ventura J, Fung AT, for International Ozurdex Study Group, et al (2020) Safety of 6000 intravitreal dexamethasone implants. Br J Ophthalmol. 104 (1): 39-46. https://doi.org/10.1136/bjophthalmol-2019-313991.
[21]	Lu Y, Gu X, Yu X et al (2019) Comparative study of intravitreal dexamethasone implant in the treatment of macular edema secondary to central retinal vein occlusion with different ages. Chin J Exp Ophthalmol. 5 (37), 363-368. https://doi.org/10.3760/cma.j.issn.2095-0160.2019.05.009.

Cite This Article

Plain Text BibTeX RIS

APA Style

Xuemei Liang, Baiyun Shen•Zuguo Ou, Hongmei An, Li Li. (2022). Long-Term Observation of Intravitreal Injection of Ranibizumab Combined with Ozurdex® in the Treatment of Retinal Vein Occlusion with Macular Edema. International Journal of Ophthalmology & Visual Science, 7(4), 126-130. https://doi.org/10.11648/j.ijovs.20220704.14

Copy | Download

ACS Style

Xuemei Liang; Baiyun Shen•Zuguo Ou; Hongmei An; Li Li. Long-Term Observation of Intravitreal Injection of Ranibizumab Combined with Ozurdex® in the Treatment of Retinal Vein Occlusion with Macular Edema. Int. J. Ophthalmol. Vis. Sci. 2022, 7(4), 126-130. doi: 10.11648/j.ijovs.20220704.14

Copy | Download

AMA Style

Xuemei Liang, Baiyun Shen•Zuguo Ou, Hongmei An, Li Li. Long-Term Observation of Intravitreal Injection of Ranibizumab Combined with Ozurdex® in the Treatment of Retinal Vein Occlusion with Macular Edema. Int J Ophthalmol Vis Sci. 2022;7(4):126-130. doi: 10.11648/j.ijovs.20220704.14

Copy | Download

@article{10.11648/j.ijovs.20220704.14,
  author = {Xuemei Liang and Baiyun Shen•Zuguo Ou and Hongmei An and Li Li},
  title = {Long-Term Observation of Intravitreal Injection of Ranibizumab Combined with Ozurdex® in the Treatment of Retinal Vein Occlusion with Macular Edema},
  journal = {International Journal of Ophthalmology & Visual Science},
  volume = {7},
  number = {4},
  pages = {126-130},
  doi = {10.11648/j.ijovs.20220704.14},
  url = {https://doi.org/10.11648/j.ijovs.20220704.14},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijovs.20220704.14},
  abstract = {Background: To evaluate the duration and long-term efficacy of intravitreal injection of ranibizumab (IVR) combined with Ozurdex® (DEX) in the treatment of retinal vein occlusion with macular edema (RVO-ME). Methods: This retrospective case study included 38 patients with non-ischemic RVO-ME who were initially treated by intravitreal injection of IVR combined with DEX. Patients with recurrence of macular edema continued with IVR+DEX therapy. Data were recorded for all patients at baseline and at 1 week, and 1, 3, 4, 5, 6, 9, and 12 months after treatment. The primary outcome measures were the average reinjection interval and the number of injection needles. Results: The mean interval for reinjection of RVO-ME was 134.2±9.1 days. The average number of injection needles was 4.2±1.1, and 65.8% of patients received 4 injection needles. There was no significant difference in mean reinjection interval and injection needle between central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO) patients. At the end of follow-up, the mean improvement of BCVA in CRVO and BRVO patients was 0.29±0.26 and 0.31±0.33, respectively, and 52.6% (20/38) patients experienced visual acuity improvement of > 3 lines. The average decrease in CFT was 406.0±272.3 μm and 408.2±379.9 μm, respectively, and there was no significant difference between the two types of RVO-ME in BCVA improvement and CFT reduction (p=0.82 and 0.98). Conclusions: Intravitreal injection of ranibizumab combined with Ozurdex® led to better efficacy, fewer injections, lower medical burden, and more controllable side effects.},
 year = {2022}
}

Copy | Download

TY  - JOUR
T1  - Long-Term Observation of Intravitreal Injection of Ranibizumab Combined with Ozurdex® in the Treatment of Retinal Vein Occlusion with Macular Edema
AU  - Xuemei Liang
AU  - Baiyun Shen•Zuguo Ou
AU  - Hongmei An
AU  - Li Li
Y1  - 2022/11/22
PY  - 2022
N1  - https://doi.org/10.11648/j.ijovs.20220704.14
DO  - 10.11648/j.ijovs.20220704.14
T2  - International Journal of Ophthalmology & Visual Science
JF  - International Journal of Ophthalmology & Visual Science
JO  - International Journal of Ophthalmology & Visual Science
SP  - 126
EP  - 130
PB  - Science Publishing Group
SN  - 2637-3858
UR  - https://doi.org/10.11648/j.ijovs.20220704.14
AB  - Background: To evaluate the duration and long-term efficacy of intravitreal injection of ranibizumab (IVR) combined with Ozurdex® (DEX) in the treatment of retinal vein occlusion with macular edema (RVO-ME). Methods: This retrospective case study included 38 patients with non-ischemic RVO-ME who were initially treated by intravitreal injection of IVR combined with DEX. Patients with recurrence of macular edema continued with IVR+DEX therapy. Data were recorded for all patients at baseline and at 1 week, and 1, 3, 4, 5, 6, 9, and 12 months after treatment. The primary outcome measures were the average reinjection interval and the number of injection needles. Results: The mean interval for reinjection of RVO-ME was 134.2±9.1 days. The average number of injection needles was 4.2±1.1, and 65.8% of patients received 4 injection needles. There was no significant difference in mean reinjection interval and injection needle between central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO) patients. At the end of follow-up, the mean improvement of BCVA in CRVO and BRVO patients was 0.29±0.26 and 0.31±0.33, respectively, and 52.6% (20/38) patients experienced visual acuity improvement of > 3 lines. The average decrease in CFT was 406.0±272.3 μm and 408.2±379.9 μm, respectively, and there was no significant difference between the two types of RVO-ME in BCVA improvement and CFT reduction (p=0.82 and 0.98). Conclusions: Intravitreal injection of ranibizumab combined with Ozurdex® led to better efficacy, fewer injections, lower medical burden, and more controllable side effects.
VL  - 7
IS  - 4
ER  -

Copy | Download

Author Information

Xuemei Liang

Department of Fundus Diseases, Nanning Aier Eye Hospital, Nanning, China
Baiyun Shen•Zuguo Ou
Hongmei An

Department of Fundus Diseases, Nanning Aier Eye Hospital, Nanning, China
Li Li

Department of Fundus Diseases, Nanning Aier Eye Hospital, Nanning, China

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Xuemei Liang, Baiyun Shen•Zuguo Ou, Hongmei An, Li Li. (2022). Long-Term Observation of Intravitreal Injection of Ranibizumab Combined with Ozurdex® in the Treatment of Retinal Vein Occlusion with Macular Edema. International Journal of Ophthalmology & Visual Science, 7(4), 126-130. https://doi.org/10.11648/j.ijovs.20220704.14

Copy | Download

ACS Style

Xuemei Liang; Baiyun Shen•Zuguo Ou; Hongmei An; Li Li. Long-Term Observation of Intravitreal Injection of Ranibizumab Combined with Ozurdex® in the Treatment of Retinal Vein Occlusion with Macular Edema. Int. J. Ophthalmol. Vis. Sci. 2022, 7(4), 126-130. doi: 10.11648/j.ijovs.20220704.14

Copy | Download

AMA Style

Xuemei Liang, Baiyun Shen•Zuguo Ou, Hongmei An, Li Li. Long-Term Observation of Intravitreal Injection of Ranibizumab Combined with Ozurdex® in the Treatment of Retinal Vein Occlusion with Macular Edema. Int J Ophthalmol Vis Sci. 2022;7(4):126-130. doi: 10.11648/j.ijovs.20220704.14

Copy | Download

@article{10.11648/j.ijovs.20220704.14,
  author = {Xuemei Liang and Baiyun Shen•Zuguo Ou and Hongmei An and Li Li},
  title = {Long-Term Observation of Intravitreal Injection of Ranibizumab Combined with Ozurdex® in the Treatment of Retinal Vein Occlusion with Macular Edema},
  journal = {International Journal of Ophthalmology & Visual Science},
  volume = {7},
  number = {4},
  pages = {126-130},
  doi = {10.11648/j.ijovs.20220704.14},
  url = {https://doi.org/10.11648/j.ijovs.20220704.14},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijovs.20220704.14},
  abstract = {Background: To evaluate the duration and long-term efficacy of intravitreal injection of ranibizumab (IVR) combined with Ozurdex® (DEX) in the treatment of retinal vein occlusion with macular edema (RVO-ME). Methods: This retrospective case study included 38 patients with non-ischemic RVO-ME who were initially treated by intravitreal injection of IVR combined with DEX. Patients with recurrence of macular edema continued with IVR+DEX therapy. Data were recorded for all patients at baseline and at 1 week, and 1, 3, 4, 5, 6, 9, and 12 months after treatment. The primary outcome measures were the average reinjection interval and the number of injection needles. Results: The mean interval for reinjection of RVO-ME was 134.2±9.1 days. The average number of injection needles was 4.2±1.1, and 65.8% of patients received 4 injection needles. There was no significant difference in mean reinjection interval and injection needle between central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO) patients. At the end of follow-up, the mean improvement of BCVA in CRVO and BRVO patients was 0.29±0.26 and 0.31±0.33, respectively, and 52.6% (20/38) patients experienced visual acuity improvement of > 3 lines. The average decrease in CFT was 406.0±272.3 μm and 408.2±379.9 μm, respectively, and there was no significant difference between the two types of RVO-ME in BCVA improvement and CFT reduction (p=0.82 and 0.98). Conclusions: Intravitreal injection of ranibizumab combined with Ozurdex® led to better efficacy, fewer injections, lower medical burden, and more controllable side effects.},
 year = {2022}
}

Copy | Download

TY  - JOUR
T1  - Long-Term Observation of Intravitreal Injection of Ranibizumab Combined with Ozurdex® in the Treatment of Retinal Vein Occlusion with Macular Edema
AU  - Xuemei Liang
AU  - Baiyun Shen•Zuguo Ou
AU  - Hongmei An
AU  - Li Li
Y1  - 2022/11/22
PY  - 2022
N1  - https://doi.org/10.11648/j.ijovs.20220704.14
DO  - 10.11648/j.ijovs.20220704.14
T2  - International Journal of Ophthalmology & Visual Science
JF  - International Journal of Ophthalmology & Visual Science
JO  - International Journal of Ophthalmology & Visual Science
SP  - 126
EP  - 130
PB  - Science Publishing Group
SN  - 2637-3858
UR  - https://doi.org/10.11648/j.ijovs.20220704.14
AB  - Background: To evaluate the duration and long-term efficacy of intravitreal injection of ranibizumab (IVR) combined with Ozurdex® (DEX) in the treatment of retinal vein occlusion with macular edema (RVO-ME). Methods: This retrospective case study included 38 patients with non-ischemic RVO-ME who were initially treated by intravitreal injection of IVR combined with DEX. Patients with recurrence of macular edema continued with IVR+DEX therapy. Data were recorded for all patients at baseline and at 1 week, and 1, 3, 4, 5, 6, 9, and 12 months after treatment. The primary outcome measures were the average reinjection interval and the number of injection needles. Results: The mean interval for reinjection of RVO-ME was 134.2±9.1 days. The average number of injection needles was 4.2±1.1, and 65.8% of patients received 4 injection needles. There was no significant difference in mean reinjection interval and injection needle between central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO) patients. At the end of follow-up, the mean improvement of BCVA in CRVO and BRVO patients was 0.29±0.26 and 0.31±0.33, respectively, and 52.6% (20/38) patients experienced visual acuity improvement of > 3 lines. The average decrease in CFT was 406.0±272.3 μm and 408.2±379.9 μm, respectively, and there was no significant difference between the two types of RVO-ME in BCVA improvement and CFT reduction (p=0.82 and 0.98). Conclusions: Intravitreal injection of ranibizumab combined with Ozurdex® led to better efficacy, fewer injections, lower medical burden, and more controllable side effects.
VL  - 7
IS  - 4
ER  -

Copy | Download